Loading, Please Wait...
WALTHAM, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced the appointment of Nancy Griffith, Ph.D., as vice president, scientific communications and medical operations, reporting to Brian Robinson, M.D., senior vice president, medical affairs. Dr. Griffith will be responsible for the creation and implementation of AMAG’s medical communications and publication strategies.
“As AMAG continues to invest in development-stage assets such as AMAG-423 and ciraparantag, it is increasingly important to effectively communicate and publish the clinical data supporting these therapies,” said Dr. Robinson. “Dr. Griffith brings the leadership and expertise necessary to develop robust medical communications and publication strategies, adding value to our strategic medical affairs objectives.”
Dr. Griffith brings more than 20 years of publications and communications experience from both large and small pharmaceutical and biotechnology companies to her new role. Most recently she served as vice president, medical operations and communications at Wave Life Sciences where she established the medical affairs function to support pipeline growth, including the development and execution of medical communications, medical publications, medical information, and scientific writing for the company’s portfolio.
Dr. Griffith earned a Doctor of Philosophy in Experimental Psychology from Temple University as well as a Bachelor’s of Science in Psychology from the University of Iowa.
Inducement Equity Awards
In connection with Dr. Griffith entering into employment with AMAG, the Board of Directors of AMAG approved inducement awards to Dr. Griffith of (i) an option to purchase 17,666 shares of common stock and (ii) 3,785 restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of the grant date. The option will have a ten-year term and be subject to the terms and conditions of the stock option agreement pursuant to which the option will be granted. The restricted stock units will vest in three equal annual installments beginning on the first anniversary of the grant date and will be subject to the restricted stock unit agreement pursuant to which the restricted stock units will be granted. These equity awards will be granted without stockholder approval as inducements material to Ms. Griffith entering into employment with AMAG in accordance with NASDAQ Listing Rule 5635(c)(4).
AMAG is a pharmaceutical company focused on bringing innovative products to patients with unmet medical needs. The company does this by leveraging its development and commercial expertise to invest in and grow its pharmaceutical products across a range of therapeutic areas, including women’s health. For additional company information, please visit www.amagpharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding Dr. Griffith’s responsibilities at AMAG related to the company’s medical communications and publication strategy and beliefs that Dr. Griffith’s leadership and expertise will add value to AMAG’s strategic medical affairs objectives are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, those risks identified in AMAG’s filings with the U.S. Securities and Exchange Commission (the SEC), including its Annual Report on Form 10‐K for the year ended December 31, 2018, and subsequent filings with the SEC, which are available at the SEC’s website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect AMAG’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on AMAG’s stock price. AMAG cautions you not to place undue reliance on any forward‐looking statements, which speak only as of the date they are made.
AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward‐looking statements.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals Contacts: